Director David R. Epstein filed a Form 4 with the SEC on November 16, 2026, disclosing four open-market purchases of AgomAb Therapeutics NV common shares on November 13, 2026.
Key Highlights
- Reporting person: David R. Epstein, identified as a Director of AgomAb Therapeutics NV (NASDAQ:AGMB).
- Total shares acquired: 14,980 common shares across four separate purchase transactions on November 13, 2026.
- Purchase prices: Transactions occurred at $5.99, $6.00, $5.75, and $6.02 per share, according to the filing.
- Post-transaction ownership: Following all reported transactions, Epstein directly beneficially owned 54,980 common shares.
- Transaction code: All four transactions were coded "P" (open-market purchase) with no derivative securities activity reported.
- ADS note: The filing states the common shares "may be represented by American Depositary Shares, each of which currently represents one common share."
Epstein's Four Purchases of AgomAb Common Shares on November 13, 2026
According to the Form 4 filed by attorney-in-fact Ellen Lefever on November 16, 2026, Director David R. Epstein made four separate purchases of AgomAb Therapeutics NV common shares on November 13, 2026. The first transaction involved 5,000 shares acquired at $5.99 per share, bringing his directly held total to 45,000 shares. A second purchase of 20 shares at $6.00 per share followed, raising the total to 45,020 shares.
The third transaction was a purchase of 5,000 shares at $5.75 per share, increasing his direct holdings to 50,020 shares. The fourth and final transaction on that date was a purchase of 4,960 shares at $6.02 per share, bringing his cumulative directly held common shares to 54,980 following all reported transactions. All four transactions were designated with transaction code "P," indicating open-market purchases, as reported in Table I of the filing.
No derivative securities activity was reported in Table II. The filing was made pursuant to Section 16(a) of the Securities Exchange Act of 1934 and covers transactions in AgomAb Therapeutics NV, listed on NASDAQ:AGMB. Epstein's address of record is listed as c/o AgomAb Therapeutics NV, Posthoflei 1/6, Antwerp, Belgium.
What Was Disclosed
Director David R. Epstein disclosed four open-market purchases of AgomAb Therapeutics NV common shares on November 13, 2026, totaling 14,980 shares at prices ranging from $5.75 to $6.02, resulting in direct beneficial ownership of 54,980 shares.





Please wait processing your request...